From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
暂无分享,去创建一个
[1] G. Fulcher,et al. Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man. , 1992, Clinical science.
[2] A. Chang,et al. Aging and insulin secretion. , 2003, American journal of physiology. Endocrinology and metabolism.
[3] Olle Ljunqvist,et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.
[4] L. Groop,et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.
[5] R. DeFronzo,et al. Lipid Infusion Decreases the Expression of Nuclear Encoded Mitochondrial Genes and Increases the Expression of Extracellular Matrix Genes in Human Skeletal Muscle* , 2005, Journal of Biological Chemistry.
[6] Xiaohui S. Xie,et al. Errα and Gabpa/b specify PGC-1α-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle , 2004 .
[7] L. Mandarino,et al. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. , 1987, The Journal of clinical investigation.
[8] H. Stefánsson,et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.
[9] K. Petersen,et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. , 2002, The Journal of clinical investigation.
[10] J. Holst,et al. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.
[11] R. DeFronzo,et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. , 2005, The Journal of clinical endocrinology and metabolism.
[12] T. M. Hayes,et al. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 2004, Diabetologia.
[13] W. A. Müller,et al. Studies of pancreatic alpha cell function in normal and diabetic subjects. , 1970, The Journal of clinical investigation.
[14] E. Ferrannini,et al. Effect of PPAR-γ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells , 2004 .
[15] V. Noé,et al. DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. , 2001, American journal of physiology. Endocrinology and metabolism.
[16] M. Hanefeld,et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.
[17] H. Noushmehr,et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.
[18] Margaret S. Wu,et al. Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.
[19] J. Gulcher,et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes , 2007, Nature Genetics.
[20] B V Howard,et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. , 1988, The New England journal of medicine.
[21] R. DeFronzo,et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.
[22] R. DeFronzo,et al. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. , 1989, Metabolism: clinical and experimental.
[23] E. Ferrannini,et al. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review , 2006, Diabetologia.
[24] R. DeFronzo,et al. Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance , 1995, Journal of the Society for Gynecologic Investigation.
[25] R. Klein,et al. Role of brain insulin receptor in control of body weight and reproduction. , 2006, Science.
[26] C. Kahn,et al. Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.
[27] B. Howard,et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.
[28] A. Duttaroy,et al. Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog , 2009, Diabetes.
[29] R. Bergman. Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach , 1989, Diabetes.
[30] R. DeFronzo,et al. LACK OF A GASTROINTESTINAL MEDIATOR OF INSULIN ACTION IN MATURITY-ONSET DIABETES , 1978, The Lancet.
[31] M. Quon,et al. Insulin-stimulated Activation of eNOS Is Independent of Ca2+ but Requires Phosphorylation by Akt at Ser1179 * , 2001, The Journal of Biological Chemistry.
[32] M. Matsuda,et al. The relative contributions of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups , 2007 .
[33] N. Ruderman,et al. Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α , 2002 .
[34] R. DeFronzo,et al. Physiological and Molecular Determinants of Insulin Action in the Baboon , 2008, Diabetes.
[35] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[36] M. Matsuda,et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. , 2007, American journal of physiology. Endocrinology and metabolism.
[37] R. DeFronzo,et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. , 2005, Diabetes.
[38] L. Mandarino,et al. Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM. , 1996, The American journal of physiology.
[39] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[40] Masafumi Matsuda,et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.
[41] L. Ryysy,et al. Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.
[42] J. Dominguez,et al. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. , 1997, Journal of the American Society of Nephrology : JASN.
[43] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[44] R. Urquhart,et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. , 2005, Diabetes care.
[45] D. Klonoff,et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.
[46] I. Vauhkonen,et al. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands. , 1998, The Journal of clinical investigation.
[47] D. Pyke. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics , 1981, British medical journal.
[48] T. Vilsbøll,et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes , 2009, Diabetologia.
[49] R. DeFronzo,et al. Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus , 2006, Expert review of endocrinology & metabolism.
[50] R. Holman,et al. UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes , 1998, Diabetes Care.
[51] S. Haffner,et al. Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes. , 1996, The Journal of clinical endocrinology and metabolism.
[52] E. Ferrannini,et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. , 1987, Metabolism: clinical and experimental.
[53] V. M. Shapiro,et al. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. , 2001, Life sciences.
[54] R. DeFronzo. The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.
[55] R. DeFronzo,et al. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. , 2002, Diabetes.
[56] G. Shulman,et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.
[57] B. Ohlsson,et al. Oxysterols induce interleukin‐1β production in human macrophages , 2002, European journal of clinical investigation.
[58] J. Holst,et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. , 2007, The Journal of clinical endocrinology and metabolism.
[59] R. DeFronzo,et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.
[60] E. Ferrannini,et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.
[61] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[62] Y. Terauchi,et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. , 2004, Diabetes.
[63] C Cobelli,et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. , 1996, Diabetes.
[64] R. Hoeldtke,et al. Counterregulatory Hormone Release and Glucose Recovery After Hypoglycemia in Non-insulin-dependent Diabetic Patients , 1983, Diabetes.
[65] J. Rogers,et al. A second-generation genetic linkage map of the baboon (Papio hamadryas) genome. , 2006, Genomics.
[66] M. Hanefeld,et al. Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study , 2005, Diabetes/metabolism research and reviews.
[67] W. James. The fundamental drivers of the obesity epidemic , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[68] R. DeFronzo,et al. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. , 1995, The American journal of physiology.
[69] E. A. Sims,et al. Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis. , 1977, Metabolism: clinical and experimental.
[70] L. Groop,et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.
[71] G. Cooney,et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. , 2000, American journal of physiology. Endocrinology and metabolism.
[72] C. Kendziorski,et al. PGC-1alpha at the crossroads of type 2 diabetes. , 2003, Nature genetics.
[73] L. J. Hardies,et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. , 2007, Diabetologia.
[74] S. Haffner,et al. Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans , 1995, Diabetes.
[75] Chari D Smith,et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. , 2005, Diabetes.
[76] R. DeFronzo,et al. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. , 1996, The Journal of clinical endocrinology and metabolism.
[77] L. Mandarino,et al. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. , 1988, Metabolism: clinical and experimental.
[78] J. Rosenstock,et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.
[79] R. DeFronzo,et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. , 2004, Diabetes.
[80] R. DeFronzo,et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. , 1987, The Journal of clinical investigation.
[81] Rury R Holman,et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). , 2002, Diabetes care.
[82] L. Groop,et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. , 1991, The Journal of clinical endocrinology and metabolism.
[83] E. Ravussin,et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. , 1993, The New England journal of medicine.
[84] Y. Miyazaki,et al. The Effect of Pioglitazone on the Liver , 2006, Diabetes Care.
[85] J. Holst,et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.
[86] R. Shulman,et al. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.
[87] Vittorio Cacciatori,et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. , 2002, Diabetes care.
[88] Rury R. Holman,et al. Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .
[89] J. Brüning,et al. Central insulin action in energy and glucose homeostasis. , 2006, The Journal of clinical investigation.
[90] D. Drucker,et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. , 2003, Diabetes.
[91] R. DeFronzo,et al. Effect of fatty acids on glucose production and utilization in man. , 1983, The Journal of clinical investigation.
[92] M. Matsuda,et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.
[93] J. Hardies,et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.
[94] K. Zierler,et al. ROLES OF INSULIN AND GROWTH HORMONE, BASED ON STUDIES ON FOREARM METABOLISM IN MAN , 1963, Medicine.
[95] A. Consoli,et al. Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. , 1990, The Journal of clinical investigation.
[96] Peter Almgren,et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. , 2007, The Journal of clinical investigation.
[97] Z Trajanoski,et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. , 1999, The New England journal of medicine.
[98] J. Levy,et al. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.
[99] W. Butterfield,et al. Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin and insulin sensitivity tests , 1965, Diabetologia.
[100] R. Bergman,et al. Exenatide can reduce glucose independent of islet hormones or gastric emptying. , 2008, American journal of physiology. Endocrinology and metabolism.
[101] L. J. Hardies,et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.
[102] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[103] M. Matsuda,et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.
[104] R. N. Bergman,et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study , 1992, The Lancet.
[105] S. Mudaliar,et al. Combination therapy for type 2 diabetes. , 1999, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[106] W. J. Andrews,et al. Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.
[107] P. Marchetti,et al. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. , 2004, Endocrinology.
[108] R. DeFronzo. Dysfunctional fat cells, lipotoxicity and type 2 diabetes , 2004, International journal of clinical practice. Supplement.
[109] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[110] L. J. Hardies,et al. Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus , 2007, Diabetologia.
[111] R. DeFronzo,et al. Metformin: A review of its metabolic effects , 1998 .
[112] B. Draznin,et al. Molecular mechanisms of insulin resistance that impact cardiovascular biology. , 2004, Diabetes.
[113] Dennis D. Kim,et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study , 2007, Diabetologia.
[114] R. Henry,et al. Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.
[115] Giovanni Pacini,et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. , 2005, Diabetes care.
[116] C. Bogardus,et al. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. , 2001, Diabetes care.
[117] R. DeFronzo,et al. Physical training and insulin sensitivity. , 1986, Diabetes/metabolism reviews.
[118] P. Bennett,et al. The natural history of impaired glucose tolerance in the Pima Indians. , 1988, The New England journal of medicine.
[119] Y. Miyazaki,et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.
[120] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[121] K. Tsuda,et al. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide , 2006, Diabetologia.
[122] K. Kim,et al. Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase. , 1977, The Journal of biological chemistry.
[123] R. DeFronzo,et al. The insulin resistance syndrome: physiological considerations , 2007, Diabetes & vascular disease research.
[124] G. Bray,et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity , 2008, Expert review of cardiovascular therapy.
[125] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[126] J. Holst,et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.
[127] E. Wilander,et al. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets , 1989, Diabetologia.
[128] A. Vaag,et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.
[129] D R Hadden,et al. Beta‐cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10‐year follow‐up of the Belfast Diet Study , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[130] R. DeFronzo,et al. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[131] J. A. Scarlett,et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. , 1981, The Journal of clinical investigation.
[132] U. Boggi,et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. , 2002, Diabetes.
[133] A. Krolewski,et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. , 1990, Annals of internal medicine.
[134] R. DeFronzo,et al. Regulation of hepatic glucose metabolism in humans. , 1987, Diabetes/metabolism reviews.
[135] R. DeFronzo,et al. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. , 2001, Diabetes.
[136] Leif Groop,et al. Genes and type 2 diabetes mellitus , 2008, Current diabetes reports.
[137] Ralph A. DeFronzo,et al. Metabolic and molecular basis of insulin resistance , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[138] R. Shulman,et al. Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy. , 1985, The Journal of clinical investigation.
[139] G. Reaven,et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. , 1985, The Journal of clinical endocrinology and metabolism.
[140] R G Shulman,et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. , 1990, The New England journal of medicine.
[141] R. DeFronzo,et al. Contributions of -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose , 2006 .
[142] A. Farmer,et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. , 2007, The New England journal of medicine.
[143] B. Rn,et al. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. , 1989 .
[144] R. DeFronzo,et al. Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.
[145] S. Woods,et al. Central nervous system control of food intake , 2000, Nature.
[146] K. Flegal,et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. , 2004, JAMA.
[147] B. Ludvik,et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans , 2004, Diabetologia.
[148] J. Leahy,et al. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. , 1986, The Journal of clinical investigation.
[149] L. Mandarino,et al. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. , 2000, Diabetes.
[150] H. Makino,et al. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. , 1989, Biochemical and biophysical research communications.
[151] C. Bogardus,et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. , 2001, Diabetes.
[152] Robert A. Rizza,et al. β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.
[153] L. Orci,et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[154] R. DeFronzo,et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. , 2008, American journal of physiology. Endocrinology and metabolism.
[155] G. Reaven,et al. Effect of Age on Glucose Tolerance, Insulin Secretion, and in Vivo Insulin Action , 1982, Journal of the American Geriatrics Society.
[156] M. Hanefeld,et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study* , 2006, Current medical research and opinion.
[157] C. Kahn,et al. Critical nodes in signalling pathways: insights into insulin action , 2006, Nature Reviews Molecular Cell Biology.
[158] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[159] R. DeFronzo,et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.
[160] T. Harrison. Faculty Opinions recommendation of Lifestyle intervention for pre-diabetic neuropathy. , 2006 .
[161] M. Nauck,et al. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.
[162] R. DeFronzo,et al. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. , 1979, The Journal of clinical investigation.
[163] J. Cha,et al. Peroxisomal Proliferator-Activated Receptor-γ Upregulates Glucokinase Gene Expression in β-Cells , 2002 .
[164] G. Reaven,et al. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance , 2004, Diabetologia.
[165] R. Pipek,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Effects of Insulin on Subcellular Localization of Hexokinase II in Human Skeletal Muscle in Vivo * , 2022 .
[166] W. Rathmann,et al. Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy , 2008, Diabetes Care.
[167] R. Vigneri,et al. Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. , 2002, Diabetes.
[168] A. Golay,et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. , 1987, The Journal of clinical endocrinology and metabolism.
[169] Y. Miyazaki,et al. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. , 2003, Diabetes.
[170] Zhaohui Feng,et al. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats , 2002, Nature Neuroscience.
[171] S. Majumdar,et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.
[172] R. DeFronzo,et al. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[173] P. Marchetti,et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. , 1999, European journal of pharmacology.
[174] R. Rizza,et al. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. , 1987, Metabolism: clinical and experimental.
[175] L. J. Hardies,et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.
[176] D. Nathan. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.
[177] J. Holst,et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.
[178] J. Holst. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 , 2006, Diabetologia.
[179] D. Einhorn,et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. , 2000, Clinical therapeutics.
[180] S. Mudaliar,et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. , 2002, Diabetes.
[181] G. Reaven,et al. Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes. , 1988, The Journal of clinical investigation.
[182] R. DeFronzo,et al. Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man , 1983, Diabetes.
[183] J. Clore,et al. Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. , 2000, Diabetes.
[184] T. Buchanan,et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.
[185] R. DeFronzo,et al. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.
[186] Y. Miyazaki,et al. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients , 2008, Diabetes, obesity & metabolism.
[187] L. Rossetti,et al. Central melanocortin receptors regulate insulin action. , 2001, The Journal of clinical investigation.
[188] U. Boggi,et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. , 2002, Diabetes.
[189] G. Shulman,et al. Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle* , 2002, The Journal of Biological Chemistry.
[190] P T Fox,et al. Altered hypothalamic function in response to glucose ingestion in obese humans. , 1999, Diabetes.
[191] R. DeFronzo,et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. , 2005, Diabetes.
[192] J. Leahy,et al. Impaired Insulin Secretion Associated With Near Normoglycemia: Study in Normal Rats With 96-h In Vivo Glucose Infusions , 1987, Diabetes.
[193] Y. Le Marchand-Brustel,et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. , 2003, Diabetes.
[194] P. Butler,et al. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. , 2008, Endocrine reviews.
[195] P. Bennett,et al. SEQUENTIAL CHANGES IN SERUM INSULIN CONCENTRATION DURING DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.
[196] R. Bergman,et al. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. , 2000, Diabetes.
[197] R. DeFronzo,et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. , 1985, The Journal of clinical investigation.
[198] M. Prentki,et al. Islet beta cell failure in type 2 diabetes. , 2006, The Journal of clinical investigation.
[199] C. Deacon. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes , 2007, Expert opinion on investigational drugs.
[200] S. Fowler,et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. , 2005, Diabetes.
[201] R. Bergman,et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1998, Annals of epidemiology.
[202] L. Groop,et al. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing Type 2 (non-insulin-dependent) diabetes mellitus , 1992, Diabetologia.
[203] K. Petersen,et al. Decreased Insulin-Stimulated ATP Synthesis and Phosphate Transport in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Parents , 2005, PLoS medicine.
[204] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[205] L. Goodyear,et al. Insulin resistance and improvements in signal transduction , 2006, Endocrine.
[206] R. Bonadonna,et al. Glucose metabolism in obesity and type 2 diabetes. , 1991, Diabete & metabolisme.
[207] W. Hsueh,et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. , 2005, The Journal of clinical endocrinology and metabolism.
[208] S. Bloom,et al. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes , 1989, Diabetologia.
[209] J. Meigs,et al. Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population , 2007, Diabetes Care.
[210] Á. Valverde,et al. Protein–Tyrosine Phosphatase 1B–Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-α–Induced Insulin Resistance , 2007, Diabetes.
[211] M. Hofker. Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .
[212] D. Drucker. The biology of incretin hormones. , 2006, Cell metabolism.
[213] R. Unger,et al. Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats* , 1998, The Journal of Biological Chemistry.
[214] M. Matsuda,et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.
[215] R. Unger. Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.
[216] A. Morris,et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.
[217] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[218] R. DeFronzo,et al. Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance , 2009, Diabetes.
[219] Alessandra Bertoldo,et al. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. , 2007, American journal of physiology. Endocrinology and metabolism.
[220] R. DeFronzo,et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. , 1992, Diabetes.
[221] Xiaohui Xie,et al. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[222] Dennis D. Kim,et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.
[223] M. Matsuda,et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. , 2002, Metabolism: clinical and experimental.
[224] R. Rizza,et al. High Expression Rates of Human Islet Amyloid Polypeptide Induce Endoplasmic Reticulum Stress–Mediated β-Cell Apoptosis, a Characteristic of Humans With Type 2 but Not Type 1 Diabetes , 2007, Diabetes.
[225] R. DeFronzo,et al. Role of Lipid Oxidation in Pathogenesis of Insulin Resistance of Obesity and Type II Diabetes , 1987, Diabetes.
[226] R. DeFronzo,et al. Effect of long chain triglyceride infusion on glucose metabolism in man. , 1982, Metabolism: clinical and experimental.
[227] P. Zimmet,et al. The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance , 1978, Diabetologia.
[228] R. DeFronzo,et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. , 1988, Metabolism: clinical and experimental.
[229] M. Nauck,et al. Incretins and the development of type 2 diabetes , 2006, Current diabetes reports.
[230] J. Dominguez,et al. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. , 1994, The American journal of physiology.
[231] G. Shulman,et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. , 1999, Diabetes.
[232] Y. Akanuma,et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment , 2005, Diabetologia.
[233] J. Holst,et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. , 2003, Diabetes.
[234] R. Holman,et al. UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[235] W. Hsueh,et al. Insulin signaling in the arterial wall. , 1999, The American journal of cardiology.
[236] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[237] J. Gulcher,et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution , 2007, Nature Genetics.
[238] J. Leahy,et al. Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§ , 2006 .
[239] C. Kahn,et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.
[240] W. Sheu,et al. Relationship Between Hepatic Glucose Production and Fasting Plasma Glucose Concentration in Patients With NIDDM , 1994, Diabetes.
[241] J. Rosenstock,et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study , 2006, Diabetes, obesity & metabolism.
[242] C. Mogensen. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. , 1971, Scandinavian journal of clinical and laboratory investigation.
[243] R. Kreisberg,et al. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. , 1966, Proceedings of the National Academy of Sciences of the United States of America.
[244] R. DeFronzo,et al. Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. , 1988, Diabetes/metabolism reviews.
[245] R. Hamman,et al. The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.
[246] P. Zimmet,et al. Insulin Levels and the Natural History of Glucose Intolerance in Nauruans , 1996, Diabetes.
[247] Johannes D. Veldhuis,et al. Human Islet Amyloid Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in Isolated Human Islets , 2007, Diabetes.
[248] R. Shulman,et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.
[249] B. Draznin. Molecular Mechanisms of Insulin Resistance: Serine Phosphorylation of Insulin Receptor Substrate-1 and Increased Expression of p85α , 2006, Diabetes.
[250] E. Newsholme,et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.
[251] E. Jéquier,et al. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. , 1990, Metabolism: clinical and experimental.
[252] B V Howard,et al. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. , 1984, The Journal of clinical investigation.
[253] J. Zierath,et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. , 2000, Diabetes.
[254] L. Groop,et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.
[255] K. Petersen,et al. Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans , 2001, Diabetologia.
[256] M. Prentki,et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial , 2009, Diabetologia.
[257] M. Hanefeld,et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[258] Ralph B D'Agostino,et al. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. , 2005, Diabetes.
[259] D. Kendall,et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. , 2007, Clinical therapeutics.
[260] E. Ferrannini,et al. Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. , 2004, Diabetes.
[261] D. Porte. Central Regulation of Energy Homeostasis , 2006, Diabetes.
[262] U. Boggi,et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. , 2004, American journal of physiology. Endocrinology and metabolism.
[263] R. Shulman,et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[264] V. Mootha,et al. Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.
[265] K. Petersen,et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. , 2005, The Journal of clinical investigation.
[266] J. Rosenstock,et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.
[267] T. Buchanan,et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.
[268] R. DeFronzo,et al. Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance , 2006, Diabetes.
[269] J. Olefsky,et al. Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus , 1986, Diabetes.
[270] S. Haffner,et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.
[271] Devjit Tripathy,et al. Actos Now for the prevention of diabetes (ACT NOW) study , 2009, BMC endocrine disorders.
[272] B. Portha,et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.
[273] W. Hsueh,et al. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway , 2005 .
[274] E. A. Sims,et al. Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary composition and adipose cell size. , 1974, The Journal of clinical investigation.
[275] D L Rothman,et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.
[276] A. Butte,et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[277] J. Leahy,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trialGerstein HC, and the The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (Population Health , 2007 .
[278] K. Petersen,et al. Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.
[279] A. Vannotti,et al. EFFECTS OF FAT INFUSION ON GLUCOSE TOLERANCE AND INSULIN PLASMA LEVELS. , 1964, Medicina experimentalis : International journal of experimental medicine.
[280] M. Taskinen,et al. One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients , 2009, Diabetes Care.
[281] A. Baron,et al. Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.
[282] P. Puigserver,et al. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.
[283] Peter Almgren,et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. , 2005, Diabetes.
[284] C. Betsholtz,et al. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. , 1989, The New England journal of medicine.
[285] R. DeFronzo. PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES , 1997 .
[286] B. Topp,et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. , 2001, Diabetes.
[287] R. Scharfmann,et al. Transcription Factor TCF7L2 Genetic Study in the French Population , 2006, Diabetes.
[288] A. Boulton. Treatment of prediabetic neuropathy , 2006, Current diabetes reports.
[289] R. DeFronzo,et al. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. , 1978, The Journal of clinical investigation.
[290] R. Kulkarni,et al. Wnt signaling: relevance to β-cell biology and diabetes , 2008, Trends in Endocrinology & Metabolism.
[291] S. Fowler,et al. The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[292] J. Tobin,et al. Insulin response during the oral glucose tolerance test: The role of age, sex, body fat and the pattern of fat distribution , 1996, Aging.
[293] B. Zinman,et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2006, Diabetes Care.